The inverse association between KRAS mutation and PR expression found here is in line with previous studies demonstrating a higher expression of ER and PR in low-grade serous carcinomas [38,39], although the number of KRAS-mutated serous tumours in our study was too low to make any direct comparisons [40]. The gene discussed is ESR1; the disease is serous adenocarcinoma.